Anna Berkenblit
Director/Board Member en SURROZEN, INC. .
Fortuna: 3 M $ al 31/01/2024
Perfil
Anna Berkenblit is on the board of Surrozen Operating, Inc. and Surrozen, Inc. In the past she held the position of Chief Medical Officer & Senior Vice President of ImmunoGen, Inc., Vice President for Pfizer Inc., Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc. and Senior Vice President-Clinical Development at H3 Biomedicine, Inc.
Anna Berkenblit received a graduate degree from Harvard University, a graduate degree from Massachusetts Institute of Technology, an undergraduate degree from Yale University and a doctorate from Harvard Medical School.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
IMMUNOGEN, INC.
0.04% | 29/12/2023 | 101 612 ( 0.04% ) | 3 M $ | 31/01/2024 |
Cargos activos de Anna Berkenblit
Empresas | Cargo | Inicio |
---|---|---|
SURROZEN, INC. | Director/Board Member | 01/08/2018 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 14/03/2019 |
Antiguos cargos conocidos de Anna Berkenblit.
Empresas | Cargo | Fin |
---|---|---|
IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 31/08/2023 |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01/01/2015 |
AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2013 |
PFIZER, INC. | Corporate Officer/Principal | 01/09/2011 |
Formación de Anna Berkenblit.
Harvard University | Graduate Degree |
Massachusetts Institute of Technology | Graduate Degree |
Yale University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
IMMUNOGEN, INC. | Health Technology |
PFIZER, INC. | Health Technology |
SURROZEN, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |